GLICOPROTEIN (GP) IIb/IIIa INHIBITORS FOR ACUTE STROKE TREATMENT

REFERENCES

• The NINDS rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. N. Engl. J. Med. 1995; 333: 1581–1587
   PubMed Web of Science ®Google Scholar
• Bednar M. M., Gross C. E. Antiplatelet Therapy in Acute Cerebral Ischemia. Stroke 1999; 30: 887–893
   PubMed Web of Science ®Google Scholar
• Sandercock P. for the International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a Randomized Trial of Aspirin, Subcutaneous Heparin, Both, or Neither Among 19,435 Patients with Acute Ischemic Stroke. Lancet 1997; 349: 1569–1581
   PubMed Web of Science ®Google Scholar
• Chinese Acute Stroke Trial (CAST) Collaborative Group. CAST: Randomised Placebo-Controlled Trial of Early Aspirin Use in 20,000 Patients with Acute Ischemic Stroke. Lancet 1997; 349: 1641–1649
   PubMed Web of Science ®Google Scholar
• Scarborough R. M., Kleiman N. S., Phillips D. R. Platelet Glycoprotein IIb/IIIa Antagonists. What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use?. Circulation 1999; 100: 437–444
   PubMed Web of Science ®Google Scholar
• Topol E. J. Toward a New Frontier in Myocardial Reperfusion Therapy; Emerging Platelet Preeminence. Circulation 1998; 97: 211–218
   PubMed Web of Science ®Google Scholar
• Verstraete M. Synthetic Inhibitors of Platelet Glycoprotein IIb/IIIa in Clinical Development. Circulation 2000; 101: E76–E80
   PubMed Web of Science ®Google Scholar
• Gartner T. K., Bennett J. S. The Tetrapeptide Analogue of the Cell Attachment Site of Fibronectin Inhibits Platelet Aggregation and Fibrinogen Binding to Activated Platelets. J. Biol. Chem. 1985; 160: 11891–11894
   Google Scholar
• Yasuda T., Gold H. K., Fallon J. T., Leinbach R. C., Guerrero J. L., Scudder L. E., Kanke M., Shealy D., Ross M. J., Collen D., Coller B. S. Monoclonal Antibody Against the Platelet Glycoprotein (GP) IIb/IIIa Receptor Prevents Coronary Artery Reocclusion After Reperfusion with Recombinant Tissue-Type Plasminogen Activator in Dogs. J. Clin. Invest. 1988; 81: 1284–1291
   PubMed Web of Science ®Google Scholar
• Schror K. Antiplatelet Drugs: a Comparative Review. Drugs 1995; 50: 7–28
   PubMed Web of Science ®Google Scholar
• Rote W. E., Werns S. W., Davis J. H., Feigen L. P., Kilgore K. S., Lucchesi B. R. Platelet GP IIb/IIIa Receptor Inhibition by SC-49992 Prevents Thrombosis and Rethrombosis in the Canine Carotid Artery. Cardiovasc. Res. 1993; 27: 500–507
   PubMed Web of Science ®Google Scholar
• Kaku S., Umemura K., Mizuno A., Kawasaki T., Nakashima M. Evaluation of the Disintegrin, Triflavin, in a Rat Middle Cerebral Artery Thrombosis Model. Eur. J. Pharmacol. 1997; 321: 301–305
   PubMed Web of Science ®Google Scholar
• Neumann F. J., Blasini R., Schmitt C., Alt E., Dirschinger J., Gawaz M., Kastrati A., Schomig A. Effect of Glycoprotein IIb/IIIa Receptor Blockade on Recovery of Coronary Flow and Left Ventricular Function After Placement of Coronary-Artery Stent in Acute Myocardial Infarction. Circulation 1998; 98: 2695–2701
   PubMed Web of Science ®Google Scholar
• Kaku S., Umemura K., Mizuno A., Yano S., Suzuki K. I., Kawasaki T., Nakashima M. Evaluation of a GP IIb/IIIa Antagonist YM337 in a Primate Model of Middle Cerebral Artery Thrombosis. Eur. J. Pharmacol. 1998; 345: 185–192
   PubMed Web of Science ®Google Scholar
• Choudri T. F., Hoh B. L., Zerwes H. G., Prestigiacomo C. J., Kim S. C., Connolly E. S., Kottirsch G., Pinsky D. J. Reduced Microvascular Thrombosis and Improved Outcome in Acute Murine Stroke by Inhibiting GP IIb/IIIa Receptor-Mediated Platelet Aggregation. J. Clin. Invest. 1998; 102: 1301–1310
   PubMed Web of Science ®Google Scholar
• Coller B. S., Peerschke E. I., Scudder L. E., Sullivan C. A. A Murine Monoclonal Antibody That Completely Blocks the Binding of Fibrinogen to Platelets Produces a Thrombasthenic-Like State in Normal Platelets and Binds to Glycoproteins IIb/IIIa. J. Clin. Invest. 1983; 72: 325–338
   PubMed Web of Science ®Google Scholar
• Tcheng J. E., Ellis S. G., George B. S., Kereiakis D. J., Kleiman N. S., Talley D., Wang A. L., Weisman H. F., Califf R. M. Pharmacodynamics of Chimeric Glycoprotein IIb/IIIa Integrin Antiplatelet Antibody Fab 7E3 in High-Risk Coronary Angioplasty. Circulation 1994; 90: 1757–1764
   PubMed Web of Science ®Google Scholar
• Mascelli M. A., Lance E. T., Damajaru L., Wagner C. L., Weisman H. F., Jordan R. E. Pharmacodynamic Profile of Short-Term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition with Gradual Recovery from GP IIb/IIIa Receptor Blockade. Circulation 1998; 97: 1680–1688
   PubMed Web of Science ®Google Scholar
• The EPIC Investigators. Use of Monoclonal Antibody Direct Against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty. N. Engl. J. Med. 1994; 330: 956–961
   PubMed Web of Science ®Google Scholar
• Topol E. J., Califf R. M., Weisman H. F., Ellis S. G., Tcheng J. E., Worley S., Ivanhoe R., George B. S., Fintel D., Weston M. Randomised Trial of Coronary Intervention with Antibody Against Platelet IIb/IIIa Integrin for Reduction of Clinical Restenosis: Results at Six Months. The EPIC Investigators. Lancet 1994; 343: 881–886
   PubMed Web of Science ®Google Scholar
• Topol E. J., Ferguson J. J., Weisman H. F., Tcheng J. E., Ellis S. G., Kleiman N. S., Ivanhoe R. J., Wang A. L., Miller D. P., Anderson K. M., Califf R. M. Long-Term Protection from Myocardial Ischemic Events in a Randomized Trial of Brief Integrin Beta-3 Blockade with Percutaneous Coronary Intervention. EPIC Investigators Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complications. JAMA 1997; 278: 479–484
   PubMed Web of Science ®Google Scholar
• The EPILOG Investigators. Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin During Percutaneous Coronary Revascularization. N. Engl. J. Med. 1997; 336: 1689–1696
   PubMed Web of Science ®Google Scholar
• The CAPTURE Investigators. Randomised Placebo-Controlled Trial of Abciximab Before and During Coronary Intervention in Refractory Unstable Angina. Lancet 1997; 349: 1429–1435
   PubMed Web of Science ®Google Scholar
• Saposnik G., Caplan L. R. Arteriosclerosis and the Promise of GP IIb/IIIa Inhibitors in Stroke. Arq. Neuropsiquiatr. 2000; 58: 1–10
   PubMed Web of Science ®Google Scholar
• Berkowitz S. D., Harrington R. A., Rund M. M., Tcheng J. E. Acute Profound Thrombocytopenia After C7E3 Fab (Abciximab) Therapy. Circulation 1997; 95: 809–813
   PubMed Web of Science ®Google Scholar
• Meyer B. J. Antithrombotic Drugs: Insight from Cardiology. Cerebrovasc. Dis. 1998; 8((Suppl. 5))19–27
   PubMedGoogle Scholar
• The EPISTENT Investigators. Randomised Placebo-Controlled and Balloon-Angioplasty-Controlled Trial to Assess Safety of Coronary Stenting with Use of Platelet Glycoprotein IIb/IIIa Blockade. Lancet 1998; 352: 87–92
   PubMed Web of Science ®Google Scholar
• Hartman G. D., Egbertson M. S., Halczenko W. Non-peptide Fibrinogen Receptor Antagonists. I. Discovery and Design of Exosite Inhibitors. J. Med. Chem. 1992; 35: 4640–4642
   PubMed Web of Science ®Google Scholar
• Barrett J. S., Murphy G., Peerlinck K. Pharmacokinetics and Pharmacodynamics of MK-383, a Selective Non-peptide Platelet Glycoprotein IIb/IIIa Receptor Antagonists, in Healthy Men. Clin. Pharmacol. Ther. 1994; 56: 377–388
   PubMed Web of Science ®Google Scholar
• Peerlinck K., De Lepeleire I., Golberg M., Farrell D., Barrett J., Hand E., Panebianco D., Deckmyn H., Vermylen J., Arnout J. MK-383 (L-700,462), a Selective Nonpeptide Platelet Glycoprotein IIb/IIIa Antagonists, is Active in Man. Circulation 1993; 88: 1512–1517
   PubMed Web of Science ®Google Scholar
• Harker L. A. Therapeutic Inhibition of Platelet Function in Stroke. Cerebrovasc. Dis. 1998; 8((Suppl. 5))8–18
   PubMedGoogle Scholar
• The RESTORE Investigators (Randomized Efficacy Study of Tirofiban for Outcome and Restenosis). Effects of Platelet Glycoprotein IIb/IIIa Blockade with Tirofiban on Adverse Cardiac Events in Patients with Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplast. Circulation 1997; 96: 1445–1453
   PubMed Web of Science ®Google Scholar
• Bednar B., Bednar R. A., Cook J. J. Drug-Dependent Antibodies Against GP IIb/IIIa Induce Thrombocytopenia. Circulation 1996; 94: 1–9
   PubMedGoogle Scholar
• The PRISM Study Investigators. A Comparison of Aspirin Plus Tirofiban with Aspirin Plus Heparin for Unstable Angina. N. Eng. J. Med. 1998; 338: 1498–1505
   PubMed Web of Science ®Google Scholar
• The PRISM-Plus Study Investigators. Inhibition of Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction. N. Engl. J. Med. 1998; 338: 1488–1497
   PubMed Web of Science ®Google Scholar
• Scarborough R. M., Naughton M. A., Teng W. Design of Potent and Specific Integrin Antagonists: Peptide Antagonists with High Specificity for Glycoprotein IIb/IIIa. J. Biol. Chem. 1993; 268: 1066–1073
   PubMed Web of Science ®Google Scholar
• PURSUIT Trial Investigators. Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndrome. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina. Receptor Suppression Using Integrilin Therapy. N. Engl. J. Med. 1998; 339: 436–443
   PubMed Web of Science ®Google Scholar
• The IMPACT Investigators. Randomised Placebo-Controlled Trial of Effect of Eptifibatide on Complications of Percutaneous Coronary Intervention, IMPACT-II (Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II). Lancet 1997; 349: 1422–1428
   PubMed Web of Science ®Google Scholar
• McClure M., Kleiman N. S., Berdan L. G. Thrombocytopenia in a Large, International Trial of the GP IIb/IIIa Inhibitor Eptifibatide in Patients with Acute Coronary Syndrome (Abstract). J. Am. Coll. Cardiol. 1998; 31((Suppl. A))93A
   Google Scholar
• The PARAGON Investigators. International, Randomized, Controlled Trial of Lamifiban, Heparin or Both in Unstable Angina. Circulation 1998; 97: 2386–2395
   PubMed Web of Science ®Google Scholar
• Kereiakes D. J., Broderick T. M., Roth E. M., Whang D., Shimsak T., Runyon J. P., Hattemer C., Schneider J., Lacock P., Mueller M., Abbottsmith C. W. Time Course, Magnitude, and Consistency of Platelet Inhibition by Abciximab, Tirofiban, or Eptifibatide in Patients with Unstable Angina Pectoris Undergoing Percutaneous Coronary Intervention. Am. J. Cardiol. 1999; 84: 391–395
   PubMed Web of Science ®Google Scholar
• Bhatt D. L., Topol E. J. Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. JAMA 2000; 284: 1549–1558
   PubMed Web of Science ®Google Scholar
• Simpfendorfer C., Kottke-Marchant K., Lowrie M. First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade: a Randomized, Placebo-Controlled Study of Xemilofiban in Unstable Angina with Percutaneous Coronary Interventions. Circulation 1997; 96: 76–81
   PubMed Web of Science ®Google Scholar
• Cannon C. P. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome: Results of the TIMI-12 Trial. Circulation 1998; 97: 340–349
   PubMed Web of Science ®Google Scholar
• Topol E. J., Easton J. D., Amarenco P., Califf R., Harrington R., Graffagnino C., Davis S., Diener H. C., Ferguson J., Fitzgerald D., Shuaib A., Koudstaal P. J., Theroux P., Van de Werf F., Willerson J. T., Chan R., Samuels R., Ilson B., Granett J. Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) Trial. Am. Heart J. 2000; 139: 927–933
   PubMed Web of Science ®Google Scholar
• Vorchheimer D. A., Fuster V. Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonists: the Present Challenge is Safety. Circulation 1998; 97: 312–314
   PubMed Web of Science ®Google Scholar
• The Abciximab in Ischemic Stroke Investigators. Abciximab in Acute Ischemic Stroke. A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study. Stroke 2000; 31: 601–609
   PubMed Web of Science ®Google Scholar
• Adams H. P., Bogousslavsky J., Barnathan E., Polzer J., Lecrerc J. R. Preliminary Safety Report of a Randomized, Double-Blinded, Dose Escalation Trial of Abciximab (ReoPro) in Acute Ischemic Stroke. Cerebrovasc. Dis. 1999; 9((Suppl. 1))127
   PubMedGoogle Scholar
• Christopoulos C. G., Machin S. J. A New Type of Pseudothrombocytopenia: EDTA-Mediated Agglutination of Platelets Bearing Fab Fragments of a Chimaeric Antibody. Br. J. Haematol. 1994; 87: 650–652
   PubMed Web of Science ®Google Scholar
• Sane D. C., Damaraju L. V., Topol E. J., Cabot C. F., Mascelli M. A., Harrington R. A., Simoons M. L., Califf R. M. Occurrence and Clinical Significance of Pseudothrombocytopenia During Abciximab Therapy. J. Am. Coll. Cardiol. 2000; 36: 75–83
   PubMed Web of Science ®Google Scholar